Johnson & Johnson SEC filings JNJ
Johnson & Johnson has 1,000 filings in SEC EDGAR's recent list, going back to Aug 2, 2018. Its latest annual report, Form ARS, was filed on Mar 11, 2026 for the period ended Dec 28, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 21, 2026, covering the quarter ended Sep 27, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (results of operations). The company's fiscal year ends on January 3.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 11, 2026 | — |
| DEF 14A | Proxy statement | Mar 11, 2026 | Mar 11, 2026 |
| DEFA14A | Additional proxy material | Mar 12, 2025 | — |
| DEF 14A | Proxy statement | Mar 12, 2025 | Mar 12, 2025 |
| DEFA14A | Additional proxy material | Mar 13, 2024 | — |
| DEFA14A | Additional proxy material | Mar 13, 2024 | — |
| DEF 14A | Proxy statement | Mar 13, 2024 | Apr 25, 2024 |
| DEFA14A | Additional proxy material | Jan 8, 2024 | — |
| DEFA14A | Additional proxy material | Apr 19, 2023 | — |
| DEFA14A | Additional proxy material | Apr 13, 2023 | — |
| DEFA14A | Additional proxy material | Mar 28, 2023 | — |
| DEFA14A | Additional proxy material | Mar 15, 2023 | — |
| DEFA14A | Additional proxy material | Mar 15, 2023 | — |
| DEF 14A | Proxy statement | Mar 15, 2023 | — |
| DEFA14A | Additional proxy material | Mar 17, 2022 | — |
| DEFA14A | Additional proxy material | Mar 16, 2022 | — |
| DEF 14A | Proxy statement | Mar 16, 2022 | Mar 16, 2022 |
| DEFA14A | Additional proxy material | Apr 12, 2021 | — |
| DEFA14A | Additional proxy material | Mar 10, 2021 | — |
| DEF 14A | Proxy statement | Mar 10, 2021 | Mar 10, 2021 |
| DEFA14A | Additional proxy material | Mar 31, 2020 | — |
| DEFA14A | Additional proxy material | Mar 27, 2020 | — |
| DEFA14A | Additional proxy material | Mar 11, 2020 | — |
| DEF 14A | Proxy statement | Mar 11, 2020 | Mar 11, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 2, 2020 | Mar 13, 2020 |
| DEFA14A | Additional proxy material | Apr 3, 2019 | — |
| DEFA14A | Additional proxy material | Mar 13, 2019 | — |
| DEF 14A | Proxy statement | Mar 13, 2019 | Apr 25, 2019 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.